Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater.

@article{Neoptolemos2011AmpullaryCE,
  title={Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater.},
  author={John P Neoptolemos and Michael J. Moore and Trevor F. Cox and Juan W Valle and Daniel H. Palmer and Andrew McDonald and Roddy Carter and Niall C. Tebbutt and Chris Dervenis and Dean Smith and Bengt Glimelius and Fareeda Y Coxon and François Lacaine and Mark R. Middleton and Paula Ghaneh and Claudio Bassi and Christoper Halloran and Attila Ol{\'a}h and Charlotte L Rawcliffe and Markus W. B{\"u}chler},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 18_suppl},
  pages={LBA4006}
}
LBA4006 Background: The effect of adjuvant treatment on overall survival (OS) of resected ampullary adenocarcinoma is not known. The aim was to compare the survival effect of adjuvant chemotherapy compared to observation (OBS) after resection and within the chemotherapy group to compare 5-fluorouracil/folinic acid (5-FU/FA) against gemcitabine (GEM). METHODS Patients were stratified by R0/R1 margins, randomised into three arms: (1) 5-FU/FA (FA, 20 mg/m2 iv bolus then 5-FU, 425 mg/m2, iv bolus… CONTINUE READING
9 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…